sorafenib has been researched along with Fibrosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, X; Guo, X; Huang, X; Li, X; Lin, J; Lu, Y; Tan, W; Wang, C; Xie, Y | 1 |
| Chao, CH; Chen, LH; Chen, Y; Chen, YT; Cheng, HT; Huang, HC; Huang, KH; Huang, KW; Jin, PR; Juang, IP; Lee, TY; Liao, YH; Lin, SL; Lin, TC; Liu, ZY; Sheng, YH; Su, CT; Sung, YC; Wang, HC; Wang, J | 1 |
| Bi, J; Cao, Y; Li, J; Li, Y; Liang, Q; Liu, J; Liu, Y; Yang, J; Zhou, L | 1 |
| Barbisan, LF; Cogliati, B; Da Silva, TC; de Albuquerque Landi, MF; Morais, JÁ; Oliveira, CP; Romualdo, GR; Vinken, M | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Noguchi, S; Takizawa, H; Yamauchi, Y | 1 |
| Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC | 1 |
| Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L | 1 |
| He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W | 1 |
| Daniele, B; Di Maio, M; Perrone, F | 1 |
1 review(s) available for sorafenib and Fibrosis
| Article | Year |
|---|---|
Novel therapeutic strategies for fibrotic lung disease: a review with a focus on epithelial-mesenchymal transition.
Topics: Airway Remodeling; Animals; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Inflammation Mediators; Lung; Lung Diseases; Myofibroblasts; Niacinamide; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Respiratory Mucosa; Sorafenib; Stromal Cells; Transforming Growth Factor beta | 2014 |
1 trial(s) available for sorafenib and Fibrosis
| Article | Year |
|---|---|
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fibrosis; Hand-Foot Syndrome; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiation Dosage; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
8 other study(ies) available for sorafenib and Fibrosis
| Article | Year |
|---|---|
Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fibroblast Growth Factor 1; Fibrosis; Humans; Liver Neoplasms; Mice; Myeloid-Derived Suppressor Cells; Sorafenib; Up-Regulation | 2022 |
Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis.
Topics: Animals; Collagen; Disease Models, Animal; Drug Carriers; Fibrosis; Kidney; Kidney Diseases; Ligands; Mice; Mice, Inbred C57BL; Myofibroblasts; Nanoparticles; Sorafenib; Ureteral Obstruction | 2022 |
Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
Topics: Collagen; Collagenases; Cytokines; Extracellular Matrix; Fibrosis; Glycyrrhetinic Acid; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Micelles; Prodrugs; Prospective Studies; Sorafenib | 2022 |
Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Topics: Animals; Cell Line, Tumor; Cell Survival; Coculture Techniques; Fibrosis; Hepatic Stellate Cells; Hepatocytes; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2021 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction | 2015 |
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Cell Adhesion; Cell Movement; Chemokine CCL2; Chemokine CXCL11; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Humans; Kidney Tubules; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Niacinamide; Phenylurea Compounds; Receptors, CXCR3; RNA, Messenger; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction | 2016 |
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Fibrosis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Time Factors | 2009 |